Pilar Vasquez Hinojosa, M.D Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 1417 N Ware Rd Ste 300, Mcallen, TX 78501 Phone: 956-585-4704 Fax: 956-585-6775 |
Dr. Samuel T. Garcia Jr., M. D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 4115 Pecan Blvd Ste B, Mcallen, TX 78501 Phone: 956-686-6050 Fax: 956-686-6359 |
Veronica Salazar, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 1000 E Dove Ave, Mcallen, TX 78504 Phone: 956-362-3520 Fax: 956-362-3552 |
Humberto F Nunez Uriburu, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 110 E Savannah Ave, Bldg B Suite 202, Mcallen, TX 78503 Phone: 956-686-7611 Fax: 956-618-3164 |
News Archive
Root canal work is not as bad as people think when compared to other dental procedures. Self-reporting of their dental health suggests that patients find the procedure no worse than other dental work which overturns the popular belief that root canal work is the most unpleasant dental treatment.
DJO Global, Inc., a leading global provider of medical device solutions for musculoskeletal health, vascular health and pain management, today announced financial results for its public reporting subsidiary, DJO Finance LLC, for the first quarter ended March 29, 2014.
The UK Department of Health (DOH) has said today that recipients of blood transfusions are to be excluded from donating blood in the future as a further precautionary measure against the possible risk of transmission of variant Creutzfeldt Jakob Disease (vCJD), Health Secretary John Reid announced today.
Acetaminophen (Tylenol and generics) is one of the most commonly used over-the-counter drugs in the United States. While generally safe, acetaminophen is known to cause severe liver injury if taken in high doses. But likely due to genetics, even the recommended dose can induce serious liver damage in a significant number of people.
The U.S. Food and Drug Administration today alerted health care professionals to a change in heparin manufacturing that is expected to decrease the potency of the common blood-clotting drug.
› Verified 6 days ago